Actavis Group

Actavis Launches Alprazolam ER Tablets in the U.S.

Published in Drug Week, March 9th, 2007

Actavis Group (ICEX: ACT), the international generic pharmaceuticals company, announced that it has received approval from the U.S. Food & Drug Administration to market Alprazolam ER tablets. Distribution of the product will commence in coming weeks.

Alprazolam ER tablets, the generic equivalent of Pfizer's Xanax(R) XR tablets, will be available in 0.5 mg, 1 mg, 2 mg, and 3 mg strengths. Alprazolam ER tablets are indicated for the treatment of anxiety and panic disorder.

Annual sales of Alprazolam ER tablets in the U.S. were approximately US$53.9 million for the twelve months ending December 2006 according to IMS Health data.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2007-03-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry